uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$33.77|
|52 Week High||US$25.80|
|52 Week Low||US$52.19|
|1 Month Change||17.26%|
|3 Month Change||9.15%|
|1 Year Change||-9.59%|
|3 Year Change||-7.20%|
|5 Year Change||341.44%|
|Change since IPO||131.14%|
Recent News & Updates
|QURE||US Biotechs||US Market|
Return vs Industry: QURE underperformed the US Biotechs industry which returned 31% over the past year.
Return vs Market: QURE underperformed the US Market which returned 37.5% over the past year.
Stable Share Price: QURE is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: QURE's weekly volatility (7%) has been stable over the past year.
About the Company
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington’s disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180 for the treatment of hemophilia A; AMT-190, an IV-administered adeno-associated virus (AAV) 5-based gene therapy for the treatment of Fabry disease; and AMT-150, a one-time, intrathecally-administered, AAV gene therapy for treating spinocerebellar ataxia type 3. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited.
uniQure Fundamentals Summary
|QURE fundamental statistics|
Is QURE overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|QURE income statement (TTM)|
|Cost of Revenue||US$155.94m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||6.58|
|Net Profit Margin||60.66%|
How did QURE perform over the long term?See historical performance and comparison
Is uniQure undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: QURE ($33.77) is trading below our estimate of fair value ($70.95)
Significantly Below Fair Value: QURE is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: QURE is good value based on its PE Ratio (5.1x) compared to the US Biotechs industry average (25.4x).
PE vs Market: QURE is good value based on its PE Ratio (5.1x) compared to the US market (17.9x).
Price to Earnings Growth Ratio
PEG Ratio: QURE's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: QURE is good value based on its PB Ratio (2.5x) compared to the US Biotechs industry average (3.3x).
How is uniQure forecast to perform in the next 1 to 3 years based on estimates from 16 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: QURE's earnings are forecast to decline over the next 3 years (-50.8% per year).
Earnings vs Market: QURE's earnings are forecast to decline over the next 3 years (-50.8% per year).
High Growth Earnings: QURE's earnings are forecast to decline over the next 3 years.
Revenue vs Market: QURE's revenue is expected to decline over the next 3 years (-17.9% per year).
High Growth Revenue: QURE's revenue is forecast to decline over the next 3 years (-17.9% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: QURE is forecast to be unprofitable in 3 years.
How has uniQure performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: QURE has high quality earnings.
Growing Profit Margin: QURE became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: QURE has become profitable over the past 5 years, growing earnings by 6.3% per year.
Accelerating Growth: QURE has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: QURE has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: QURE's Return on Equity (47.9%) is considered outstanding.
How is uniQure's financial position?
Financial Position Analysis
Short Term Liabilities: QURE's short term assets ($694.2M) exceed its short term liabilities ($46.1M).
Long Term Liabilities: QURE's short term assets ($694.2M) exceed its long term liabilities ($104.6M).
Debt to Equity History and Analysis
Debt Level: QURE's debt to equity ratio (11.2%) is considered satisfactory.
Reducing Debt: QURE's debt to equity ratio has reduced from 13.7% to 11.2% over the past 5 years.
Debt Coverage: QURE's debt is well covered by operating cash flow (428.5%).
Interest Coverage: QURE's interest payments on its debt are well covered by EBIT (56.8x coverage).
What is uniQure current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate QURE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate QURE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if QURE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if QURE's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of QURE's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Matt Kapusta (49 yo)
Mr. Matthew Craig Kapusta, also known as Matt, has been the Chief Executive Officer of uniQure N.V. since December 19, 2016 and served as its Chief Financial Officer until June 15, 2021. Mr. Kapusta served...
CEO Compensation Analysis
Compensation vs Market: Matt's total compensation ($USD4.47M) is about average for companies of similar size in the US market ($USD3.67M).
Compensation vs Earnings: Matt's compensation has been consistent with company performance over the past year.
Experienced Management: QURE's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Experienced Board: QURE's board of directors are considered experienced (4.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: QURE insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.1%.
uniQure N.V.'s employee growth, exchange listings and data sources
- Name: uniQure N.V.
- Ticker: QURE
- Exchange: NasdaqGS
- Founded: 1998
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.557b
- Shares outstanding: 46.11m
- Website: https://www.uniqure.com
Number of Employees
- uniQure N.V.
- Paasheuvelweg 25a
- 1105 BP
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/25 02:23|
|End of Day Share Price||2021/09/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.